Olaparib is inhibiting PARP1, PARP2, and PARP3 and is used as a therapy for cancer in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast and prostate cancers [19]. The gene discussed is PARP2; the disease is prostate cancer.